About the Conference
The fields of liquid biopsy and immuno-oncology are coming together as the pace of discovery of new targets and innovativetreatments are ramping up and requiring novel biomarkers to predict which patients will be respond to treatment, minimize toxicity
and monitor therapy. A wide range of new circulating biomarkers are being discovered and they will be vetted for their suitability for assays and use in the clinical setting. Immunotherapy advances include an expanding array of T-cell engineering
approaches, next generation molecules and companion diagnostics to guide treatment decisions.
Circulating Tumor Cells in Breast Cancers: Current Clinical Validity and Utility
François-Clément Bidard, MD, PhD, Professor of
Medical Oncology, Institut Curie & Versailles St. Quentin University
Critical Assessment of the Challenges of Using Blood-Based Biomarkers in Prostate Cancer from a Clinical Point of View
Daniel C. Danila, MD, Medical Oncology Fellow, Genitourinary Oncology Service, Department
of Medicine, Memorial Sloan Kettering Cancer Center
Biomarkers to Inform Trial Design and Combinations in Immuno-Oncology
Ron Mazumder, PhD, MBA, Vice President, Oncology Biomarker Development & Companion Diagnostics,
Genentech
The Targeted Agent and Profiling Utilization Registry Study: Rationale, Design and Preliminary Findings
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President, CMO, American
Society of Clinical Oncology
Treatment of Breast and Gynecologic Cancers with Cancer Immunotherapy
Jakob Dupont, MD, Vice President, Global Head, Breast & Gynecologic Cancer Development, Genentech